PT-141

Buy PT-141 Online

PT-141, also known as bremelanotide, is a melanocortin-receptor agonist researched primarily for sexual desire, sexual arousal, and erectile-function research.

Product Information

Bremelanotide acts on melanocortin receptors, particularly MC3R and MC4R. Human research has investigated its effects on sexual desire and arousal in both women and men.

How It Works

PT-141 works centrally through melanocortin-receptor signaling rather than through the nitric oxide pathway used by drugs such as sildenafil. This makes its mechanism particularly interesting in sexual-function research.

POTENTIAL BENEFITS

1. Sexual Desire Research

Clinical trials have demonstrated improvements in sexual desire in premenopausal women with hypoactive sexual desire disorder.

2. Sexual Arousal

Research has shown that bremelanotide can influence subjective measures of sexual arousal and desire following administration.

3. Erectile-Function Research

Clinical research has also investigated bremelanotide in men with erectile dysfunction, including men who did not respond adequately to sildenafil.

4. Libido Research

Its effects on central melanocortin signaling make PT-141 particularly interesting for research into libido and sexual motivation.

5. On-Demand Research

Unlike compounds requiring continuous exposure, bremelanotide has been investigated as an on-demand treatment taken in relation to sexual activity.

Dosage

Clinical trials of bremelanotide have used 1.75 mg subcutaneously as needed, while earlier dose-finding studies evaluated 0.75–1.75 mg. Intranasal studies also investigated other doses.

Side Effects

Commonly reported effects include nausea, flushing, and headache. Temporary increases in blood pressure can also occur.

References

• Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women's Health. 2016;12(3):325-337. PMID: 27181790. PubMed
• Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019;134(5):899-908. PMID: 31599840. PubMed
• Pfaus JG, Sadiq A, Spana C, Clayton AH. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectrums. 2022;27(3):281-289. PMID: 33455598. PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Please click here to access instructions on how to make a payment.

How to Pay